What is the role of neoadjuvant chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma?   

I think the data on neoadjuvant chemotherapy continues to show a lack of survival benefit in this disease.  I think HN001 is the preferred treatment as we give the definitive treatment, which is radiation therapy, followed by asking the question of what to do in the adjuvant setting.

We do not routinely recommend neoadjuvant chemotherapy in locoregionally advanced nasopharyngeal cancer. There is no level 1 evidence.